Study on Plasmablastic Lymphoma Patients (FIL_PlaLy)

Fondazione Italiana Linfomi - ETS

Status: Enrolling

Conditions: Plasmablastic Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT06781359

FIL_PlaLy

Details and patient eligibility

About

This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.

Full description

This study is an International, multicenter, observational, retrospective trial on patients affected by PBL. The information collected aim to obtain data from the real-life diagnosis, staging, management and treatment and outcome of PBL patients. A centralized pathological review of pathological samples is planned to define the rate of accurate diagnosis and to define a recommended immunohistochemical diagnostic panel for PBL. In addition, exploratory analysis will be performed to better characterize PBL.

Enrollment: 200 estimated patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
• Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
• Age > 18 years old
• Availability of complete medical records
• Availability of histopathological material requested by the study

Exclusion criteria

• Any other histology than PBL
• Lack of complete medical records
• Lack of histopathological material requested by the study

Trial design

200 participants in 1 patient group

Plasmablastic lymphoma patients

Description:

Patients with diagnosis (histologically confirmed) of plasmablastic lymphoma (PBL) between Jan 1st 2000 and Dec 31st 2022